Analysts at Morgan Stanley (MS) downgraded Diplomat Pharmacy, Inc. (DPLO) from ‘Overweight’ to ‘Equal-Weight’ in a research report issued to clients on Friday.
On valuation measures, Diplomat Pharmacy Inc. stock it’s trading at a forward P/E multiple of 31.68x, and at a multiple of 150.38x this year’s estimated earnings. The t-12-month revenue at Diplomat Pharmacy Inc. is $2.64 billion. DPLO ‘s ROE for the same period is 3.03%.
Shares of the $1.76 billion market cap company are up 7.78% since the beginning of the year.
Diplomat Pharmacy Inc., currently with a median Wall Street price target of $55 and a high target of $58, dropped $1.85 to $27.65 in recent trading.
Gilead Sciences Inc. (GILD) was downgraded from ‘Overweight’ to ‘Equal-Weight’ at Morgan Stanley.
Shares have traded today between $94.37 and $97.92 with the price of the stock fluctuating between $85.95 to $123.37 over the last 52 weeks.
Gilead Sciences Inc. shares are currently changing hands at 10.07x this year’s forecasted earnings, compared to the industry’s -11.03x earnings multiple. Ticker has a t-12 price/sales ratio of 4.94. EPS for the same period registers at $9.48.
Shares of GILD have lost $2.89 to $95.38 in midday trading on Friday, giving it a market cap of roughly $140 billion. The stock traded as high as $123.37 in June 24, 2015.
Dunkin’ Brands Group, Inc. (DNKN) was reiterated a ‘Neutral’ by UBS analysts on Friday. The broker cut its price target on the stock to $45 from $52, following the stock’s biggest one-day drop ever Thursday.
Fundamentally, Dunkin’ Brands shows the following financial data:
- $328.60 million in cash in most recent quarter
- $3.18 billion t-12 total assets
- $374.95 million total equity
- $783.18 million t-12 revenue
- $176.36 million annual net income
- $175.69 million free cash flow
DNKN closed at $43 on Thursday and is currently trading up $0.53.
In the past 52 weeks, shares of the doughnut chain have traded between a low of $41.55 and a high of $56.79 and are now trading at $43.53.
Shares are down 1.23% year-over-year ; up 2.46% year-to-date.
Progress Software Corporation (PRGS) was reiterated as ‘Neutral’ with a $25 from $29 price target on Friday by Wedbush.
PRGS was down $2.51 at $23.12 in midday trade, moving within a 52-week range of $21.94 to $30.57. The name, valued at $1.16 billion, opened at $22.19.